Yung Shin Pharm. Ind. Co., Ltd.

Industrial Technology Research Institute

Yung Shin Pharmaceutical Industrial Co. Ltd.

Yung Shin Pharma Ind. Co., Ltd.

Carlsbad Technology, Inc.

Tsang-Miao Huang

Fang-Yu Lee

Chao-Ho Chung

Sheng-Chu Kuo

Che-Ming Teng

On Lee

Chrong-Shiong Hwang

Fang Yu Lee

Liang-Rern Kung

Yi-Ting Hung

Tung-Shen Fang

Chi-Ying Hung

Jhih Li He

Po-Wei Chang

Chiung Ju Tsai

Chin-Yi Wu

Shin Hong Jang

Jhih-Li He

The present invention relates to a stable liquid cabazitaxel formulation in an enclosed container. The enclosed container comprises a liquid phase and an gaseous phase, wherein the liquid phase comprises cabazitaxel, polysorbate 80, ethanol, and one or more pH adjusters to maintain pH about 2.8-6.0, and the gaseous phase is saturated with CO. The present invention is also directed to a process for preparing the enclosed liquid pharmaceutical composition container.

Stable pharmaceutical formulation of cabazitaxel

The present invention is directed to an amorphous form of cabazitaxel, which can be prepared by dissolving a solid form of cabazitaxel in an organic solvent, and removing the organic solvent to dryness. The amorphous form of cabazitaxel is characterized by DSC as in FIG.and/or X-ray powder diffraction pattern as in FIG.

Amorphous cabazitaxel

The present invention synthesizes a series of novel indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl)indazole (YC-1), and their anti-platelet activity.

Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2&#x2032;-furyl) indazole (YC-1) as anti-platelet agents

Pharmaceutically acceptable salt of amlodipine and method of preparing the same

Method for producing 5-aryloxymethyl-2-oxazolidinones

Growing community of inventors

Chunghua, Taiwan

Tsang-Miao Huang